Coloplast COLO-B.CO
Coloplast is a Danish medical device company that designs and sells ostomy, urology, continence, and wound care products, with a business model based on manufacturing recurring medical consumer devices. Coloplast shows solid financial health (ND/EBITDA 2.67) and a robust competitive moat (ROIC 20.06%, gross margin 67.23%), with earnings growth of 81.80% which, although exceptional, is supported by stable organic growth of 6%. Valuation is demanding (P/E 34.18), but the forward P/E of 16.12 suggests improvement expectations; the 187.60% payout is a warning sign for dividend sustainability.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Coloplast is a Danish medical device company that designs and sells ostomy, urology, continence, and wound care products, with a business model based on manufacturing recurring medical consumer devices. Coloplast shows solid financial health (ND/EBITDA 2.67) and a robust competitive moat (ROIC 20.06%, gross margin 67.23%), with earnings growth of 81.80% which, although exceptional, is supported by stable organic growth of 6%. Valuation is demanding (P/E 34.18), but the forward P/E of 16.12 suggests improvement expectations; the 187.60% payout is a warning sign for dividend sustainability.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.7 |
| Quality / Moat | 7.6 |
| Valuation | 5.8 |
| Growth | 7.8 |
| Dividend | 4.3 |
| Momentum | 2.4 |
| Risk & Context | 8.1 |
OVERALL SCORE: 6.5/10
Context and risks
Moderate regulatory risk in Denmark due to the nature of medical devices subject to reimbursement and approvals, although without specific active litigation or investigations.
News considered in the analysis
- Coloplast AS (CLPBF) (Q3 2026) Earnings Call Highlights: Organic Growth Steady at 6% Amid US ... — Crecimiento orgánico estable del 6%, en línea con lo esperado; refuerza la confianza en la ejecución pero no es un evento transformador.
- Gieves & Hawkes’s Savile Row home sold to Danish catheter tycoon — Noticia personal del CEO, sin impacto en la operativa o valoración de la empresa.
- 3 European Stocks Possibly Trading At Discounts Of Up To 39.2% — Listículo genérico sin información específica accionable.
- Uncovering 3 European Stocks That May Be Priced Below Intrinsic Value Estimates — Listículo genérico sin información específica accionable.
- Coloplast AS (CLPBF) Q2 2026 Earnings Call Highlights: Strong Organic Growth Amidst Market ... — Resultados del Q2 ya conocidos y descontados por el mercado; el crecimiento orgánico fuerte ya está en el precio.
Verdict: Hold; business quality and growth justify the premium, but valuation and unsustainable payout limit near-term re-rating potential.
Main risk: The 187.60% payout is unsustainable and could force a dividend cut, negatively impacting the dividend score and market confidence.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →